title: [Effects of levofloxacin once-a-day therapy on uterine cervicitis].
abstract: An investigation was carried out to determine the therapeutic effect of levofloxacin (LVFX) once-a-day oral therapy at the dose of 200 mg/day for 7 days on uterine cervicitis, in comparison with LVFX twice-a-day oral therapy at the dose of 200 mg/day for 7 days. Of the 102 patients enrolled in the study, 90 were subjected to the analysis. The efficacy rate on uterine cervicitis of the once-a-day therapy and twice-a-day therapy groups according to the evaluation of the Drug Efficacy Evaluation Committee were 72.0% (36/50) and 82.5% (33/40), respectively. The efficacy rate on uterine chlamydial cervicitis of the once-a-day therapy and twice-a-day therapy groups according to the evaluation of the Drug Efficacy Evaluation Committee were 88.0% (22/25) and 85.7% (18/21), respectively. Safety was evaluated as "safe" in 88 of the 90 assessable patients (97.8%). Side effects were seen in two cases, which belong to the once-a-day therapy group; mild candidiasis and mild breast distension sense. As the antimicrobial treatment started, the levels of the inflammatory cytokines, interleukin-6 (IL-6) and interleukin-8 (IL-8) in the cervical mucus, decreased. It is suggested that IL-6 and IL-8 can be useful indicators of the antimicrobial treatment in the uterine cervicitis. These results suggested that the LVFX once-a-day therapy can be useful on uterine cervicitis.
authors.affiliation: Department of Obstetrics and Gynecology, School of Medicine, Gifu University.
authors.forename: H
authors.initials: H
authors.lastname: Mikamo
authors.forename: Y
authors.initials: Y
authors.lastname: Sato
authors.forename: Y
authors.initials: Y
authors.lastname: Hayasaki
authors.forename: T
authors.initials: T
authors.lastname: Tamaya
authors.forename: Y
authors.initials: Y
authors.lastname: Yamada
authors.forename: K
authors.initials: K
authors.lastname: Ito
authors.forename: K
authors.initials: K
authors.lastname: Izumi
authors.forename: K
authors.initials: K
authors.lastname: Kawazoe
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002690:Chlamydia Infections / Q000188:drug therapy; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D015850:Interleukin-6 / Q000032:analysis; D016209:Interleukin-8 / Q000032:analysis; D064704:Levofloxacin; D008875:Middle Aged; D009093:Mucus / Q000737:chemistry; D015242:Ofloxacin / Q000008:administration & dosage* / Q000009:adverse effects; D002575:Uterine Cervicitis / Q000188:drug therapy*
chemical_list: D000890:Anti-Infective Agents; D015850:Interleukin-6; D016209:Interleukin-8; D064704:Levofloxacin; D015242:Ofloxacin